Science, Finance, Biotech Chris Morrison Science, Finance, Biotech Chris Morrison

Raven-built Aliada shuttles its potential best-in-class Alzheimer's treatment to AbbVie

Today, AbbVie announced it is acquiring Aliada for $1.4 billion, motivated by the potential for ALIA-1758, Aliada’s lead program, to be the best-in-class for the treatment of Alzheimer’s disease, and by the potential of the BBB-crossing platform to enhance its discovery and development efforts for other difficult-to-treat neurological diseases. As we congratulate the Aliada team, we wanted to share a bit more of the story behind the second significant acquisition from our Raven incubator this year and the first full-circle acquisition of a company we built with technology spun out from a larger company.

Read More
Finance, Biotech Peter Kolchinsky Finance, Biotech Peter Kolchinsky

What makes a venture round a crossover round?

A LinkedIn discussion about “crossover” financing rounds deepened my sense that we’re not all saying the same thing when we’re saying the same thing. And that’s a challenge, if not necessarily always a problem, in an industry that’s only becoming more scientifically and financially complex as it matures. Because to understand one another and avoid unnecessary hiccups it helps to have a common language.

Read More
Finance, Policy, Biotech, Planetary Health Peter Kolchinsky Finance, Policy, Biotech, Planetary Health Peter Kolchinsky

Act now to prevent SVB’s failure from becoming a national crisis

The federal government must address the failure of Silicon Valley Bank (SVB) with speed and clarity before it metastasizes into a national crisis, so the ecosystem of institutions in which SVB has operated, including other banks and investors, can help bridge companies so that they can continue to operate while they wait for their deposits.

Read More